Praxis Precision Medicines Reports Relutrigine Shows Significant Seizure Reduction in EMBOLD Study
I'm PortAI, I can summarize articles.
Praxis Precision Medicines Inc. plans to file a New Drug Application for relutrigine in early 2026 after successful FDA discussions. The EMBOLD study showed relutrigine significantly reduced seizures in children with SCN2A and SCN8A DEEs, demonstrating robust improvements and a favorable safety profile. The results have been discussed with the FDA. This news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments